title: Nanoparticle-based passive drug targeting to tumors: considerations and implications for optimization.
abstract: There are many potential barriers to the effective delivery of small-molecule drugs to solid tumors. Most small-molecule chemotherapeutic drugs have a large volume of distribution upon intravenous administration, which is often associated with a narrow therapeutic index due to their high level of toxicity in healthy tissues. Nanoparticle-based therapeutics for tumor targeting have emerged as one of the promising approaches to overcome the lack of tissue specificity of conventional chemotherapeutic drugs. Various different concepts have been envisioned for nanoparticle-mediated drug targeting. Among them, the passive drug targeting strategy has been the most widely investigated, and numerous preclinical studies have provided insights into the validity of the strategy. This review article briefly introduces our recent findings related to the passive drug targeting strategy including its application in anti-angiogenic therapy, along with considerations to be taken into account and implications for the rational design of a passive drug targeting strategy.
authors: Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, Okayama 700–8530, Japan. ogawara@pheasant.pharm.okayama-u.ac.jp
authors: Ken-ichi
authors: K
authors: Ogawara
authors: Yuta
authors: Y
authors: Yoshizawa
authors: Keita
authors: K
authors: Un
authors: Tomoya
authors: T
authors: Araki
authors: Toshikiro
authors: T
authors: Kimura
authors: Kazutaka
authors: K
authors: Higaki
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D006801:Humans; D053758:Nanoparticles / Q000008:administration & dosage*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010539:Permeability / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents